Cystic Fibrosis Foundation (CF Foundation) to provide an award of up to $15.9 million for the ongoing ELX-02 clinical program
Expect topline data from cystic fibrosis Phase 2 expansion treatment arms evaluating combination with ivacaftor by the end of the first half of 2022
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.